Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol

Xiao-yi Tang(Academy of Military Medical Sciences), Hu Chen(Academy of Military Medical Sciences), Ang Zhang(Chinese PLA General Hospital), Danhong Wang(Academy of Military Medical Sciences), Guoliang Hu(Academy of Military Medical Sciences), Bin Zhang(Northwestern University), Yao Sun(Academy of Military Medical Sciences), Wei Cao(Academy of Military Medical Sciences)
BMJ Open
December 1, 2016
Cited by 90


Related Papers